{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:10:41Z","timestamp":1694776241140},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Artemisinin was discovered to be highly effective antimalarial drugs shortly after the isolation of the parent artemisinin in 1971 in China. It is derived from extracts of sweet wormwood (<jats:italic toggle=\"yes\">Artemisia annua<\/jats:italic>) and are well established for the treatment of malaria. Recently, artemisinin has been shown that it might have therapeutic value for several other diseases. The purpose of this review is to assess the efficacy of artemisinin as a treatment for macular edema associated with retinal vein occlusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and analysis:<\/jats:title>\n            <jats:p>A systematic literature search will be performed in all available databases to quantitatively review eligible studies and identify all relevant data. We will include randomized controlled trials assessing efficacy of artemisinin as a treatment for macular edema associated with retinal vein occlusion. The methodological qualities, including the risk of bias, will be evaluated using the Cochrane risk of bias assessment tool, while confidence in the cumulative evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>Ethical approval is not required, as this study is based on the review of published research. This review will be published in a peer-reviewed journal and disseminated both electronically and in print.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration number:<\/jats:title>\n            <jats:p>The protocol for this systematic review has been registered on PROSPERO under the number CRD42019131408.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000016044","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T17:08:51Z","timestamp":1561223331000},"page":"e16044","source":"Crossref","is-referenced-by-count":0,"title":["Intervention of artemisinin in macular edema associated with retinal vein occlusion"],"prefix":"10.1097","volume":"98","author":[{"given":"Jing","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Like","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"313.e1","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study","volume":"123","author":"Larsen","year":"2016","journal-title":"Ophthalmology"},{"key":"R3-20230914","first-page":"1192","article-title":"10-year fundus tessellation progression and retinal vein occlusion","volume":"11","author":"Yan","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"R4-20230914","first-page":"901","article-title":"Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature","volume":"33","author":"Jaulim","year":"2013"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00417-018-4095-5","article-title":"Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience","volume":"256","author":"Blanc","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ophtha.2013.11.022","article-title":"Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials","volume":"121","author":"Thach","year":"2014","journal-title":"Ophthalmology"},{"key":"R7-20230914","first-page":"429.e7","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Clark","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamaophthalmol.2017.1142","article-title":"Comparing anti-vascular endothelial growth factor therapies for central retinal vein occlusion","volume":"135","author":"Sun","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1021\/acs.biomac.8b00870","article-title":"Polycaprolactone nanofibers containing vascular endothelial growth factor-encapsulated gelatin particles enhance mesenchymal stem cell differentiation and angiogenesis of endothelial cells","volume":"19","author":"Yong-Chao","year":"2018","journal-title":"Biomacromolecules"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00417-017-3852-1","article-title":"Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months","volume":"256","author":"Winterhalter","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.apsb.2016.01.008","article-title":"Artemisinin anti-malarial drugs in China","volume":"6","author":"Guo","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"R12-20230914","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","author":"Alessandro","year":"2009","journal-title":"BMJ"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"10210","DOI":"10.1002\/anie.201601967","article-title":"Artemisinin-A gift from traditional Chinese medicine to the World (Nobel Lecture)","volume":"55","author":"Tu","year":"2016","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201906210-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:23:33Z","timestamp":1694719413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201906210-00023"}},"subtitle":["A protocol for a systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":16,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016044","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}